Hemólisis grave por ceftriaxona
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v32i1.941Resumen
.
Descargas
Referencias
Pearl RG, Sibbald WJ. Overview of ane-mia and blood management in critical care. Crit Care Med. 2003;31(12 Suppl):S649-50. DOI: https://doi.org/10.1097/00003246-200312001-00001
Harris JW. Studies on the mechanism of a drug-induced hemolytic anemia. J Lab Clin Med. 1956;47(5):760-75.
Johnson ST, Fueger JT, Gottschall JL. One center’s experience: the serology and drugs associated with drug-induced immune hemo-lytic anemia--a new paradigm. Transfusion. 2007;47(4):697-702. DOI: https://doi.org/10.1111/j.1537-2995.2007.01173.x
Packman CH. Anemia hemolítica inmune relacionada con fármacos. En: Beutler E, Li-chtman MA, Coller BS, eds., et al. Williams Hematología. Madrid: Marbán: 2007. Sec. V, Cap. 57, p. 503-8.
Garratty G. Immune cytopenia associ-ated with antibiotics. Transfus Med Rev. 1993;7(4):255-67. DOI: https://doi.org/10.1016/S0887-7963(93)70145-5
Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 2000;26(9):1390-4. DOI: https://doi.org/10.1007/s001340000598
Shulman IA, Arndt PA, McGehee W, et al. Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism. Transfusion. 1990;30(3):263-6. DOI: https://doi.org/10.1046/j.1537-2995.1990.30390194351.x
Mandell GL, Sande MA. Antimicrobial agents: penicillins, cephalosporins, and other beta-lactam antibiotics. En: Goodman Gilman A, Rall TW, Nies AS, eds., et al. Goodman and Gilman’s the pharmacological basis of thera-peutics. 8th ed. New York: Pergamon Press; 1990. Sec. XI, Cap. 46, p. 1065-97.
Quagliarello VJ, Scheld WM. Treat-ment of bacterial meningitis. N Engl J Med. 1997;336(10):708-16. DOI: https://doi.org/10.1056/NEJM199703063361007
Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexametha-sone administration in infants and children with bacterial meningitis. N Engl J Med. 1991;324(22):1525-31. DOI: https://doi.org/10.1056/NEJM199105303242201
Stankievich E, García Arrigoni P, Rodrí-guez de Schiavi S. Crisis hemolítica no fatal asociada a ceftriaxone en un niño con SIDA. Arch Argent Pediatr. 2001;99(1):49-51.
Mandell GL, Sande MA. Antimicrobial agents: penicillins, cephalosporins, and other beta-lactam antibiotics. Op cit.
Garratty G, Postoway N, Schwellenbach J, et al. A fatal case of ceftriaxone (Rocephin)-induced hemolytic anemia associated with intravascular immune hemolysis. Transfusion. 1991;31(2):176-9 DOI: https://doi.org/10.1046/j.1537-2995.1991.31291142951.x
Lascari AD, Amyot K. Fatal hemolysis caused by ceftriaxone. J Pediatr. 1995;126(5 Pt 1):816-7. DOI: https://doi.org/10.1016/S0022-3476(95)70418-3
Meyer O, Hackstein H, Hoppe B, Göbel FJ, Bein G, Salama A. Fatal immune haemol-ysis due to a degradation product of ceftriax-one. Br J Haematol. 1999;105(4):1084-5. DOI: https://doi.org/10.1046/j.1365-2141.1999.01434.x
Borgna-Pignatti C, Bezzi TM, Reverberi R. Fatal ceftriaxone-induced hemolysis in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J. 1995;14(12):1116-7. DOI: https://doi.org/10.1097/00006454-199512000-00023
Ye W, Liu CW. A case of ceftriaxone-induced haemolysis complicated by acute portal vein thrombosis. Chin Med J (Engl). 2011;124(1):152-4.
Dinesh D, Dugan N, Carter J. Intravascu-lar haemolysis in a patient on ceftriaxone with demonstration of anticeftriaxone antibodies. Intern Med J. 2008;38(6):438-41. DOI: https://doi.org/10.1111/j.1445-5994.2008.01656.x
Bernini JC, Mustafa MM, Sutor LJ, Bu-chanan GR. Fatal hemolysis induced by cef-triaxone in a child with sickle cell anemia. J Pediatr. 1995;126(5 Pt 1):813-5 DOI: https://doi.org/10.1016/S0022-3476(95)70417-5
Descargas
Compartir artículo
Publicado
Número
Sección
Licencia
Derechos de autor 2012 María del Carmen Adducci, Jorge Alejandro Vázquez, Karina Trench, Rodrigo Gómez Paz, Gerardo Dip, Carlos Coronel, Rubén Pérsico, Jorge Méndez

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.










